ArticleMolecular and cellular biochemistry2012
Involvement of ecto-5'-nucleotidase/CD73 in U138MG glioma cell adhesion.
Article in Molecular and cellular biochemistry, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 65 citations in OpenAlex.
- Cancer immunotherapy by adenosinergic CD39 and CD73 as emerging immune checkpoints.Discover oncology · 2025Review
- CD39 and CD73: biological functions, diseases and therapy.Molecular biomedicine · 2025Review
- Caffeinated and Decaffeinated Yerba Mate (Ilex paraguariensis) Infusion Extracts Alter CD73 and Reduce the Migration and Adhesion of Glioblastoma Cells.Plant foods for human nutrition (Dordrecht, Netherlands) · 2025Article
- Assessing Ecto-5'-Nucleotidase/CD73 Expression and Malignancy Parameters in Early- and Late- Passage C6 Glioma Cells.Neurochemical research · 2025Article
- CD73 Molecule Inhibitor Upregulates miR16 Expression in Experimental Glioblastoma and Inhibits Angiogenesis by Targeting VEGF.Journal of molecular neuroscience : MN · 2025Article
- Adenosinergic Signalling in Cervical Cancer Microenvironment.Expert reviews in molecular medicine · 2025Review
- Influence of Zika virus on the cytotoxicity, cell adhesion, apoptosis and inflammatory markers of glioblastoma cells.Oncology letters · 2024Article
- Istradefylline modulates purinergic enzymes and reduces malignancy-associated factors in B16F10 melanoma cells.Purinergic signalling · 2023Article
- Nucleic acid drug vectors for diagnosis and treatment of brain diseases.Signal transduction and targeted therapy · 2023Review
- Single cell spatial analysis reveals the topology of immunomodulatory purinergic signaling in glioblastoma.Nature communications · 2022Article
- Is the regulation by miRNAs of NTPDase1 and ecto-5'-nucleotidase genes involved with the different profiles of breast cancer subtypes?Purinergic signalling · 2022Article
- The Multifaceted Actions of CD73 During Development and Suppressive Actions of Regulatory T Cells.Frontiers in immunology · 2022Review
- A new side-effect of sufentanil: increased monocyte-endothelial adhesion.BMC anesthesiology · 2021Article
- Role of Purinome, A Complex Signaling System, In Glioblastoma Aggressiveness.Frontiers in pharmacology · 2021Article
- Adenosinergic Signaling as a Key Modulator of the Glioma Microenvironment and Reactive Astrocytes.Frontiers in neuroscience · 2021Review
- CD39 and CD73 as Promising Therapeutic Targets: What Could Be the Limitations?Frontiers in pharmacology · 2021Article
- Enzymatic Activity of CD73 Modulates Invasion of Gliomas via Epithelial-Mesenchymal Transition-Like Reprogramming.Pharmaceuticals (Basel, Switzerland) · 2020Article
- High Adenosine Extracellular Levels Induce Glioblastoma Aggressive Traits Modulating the Mesenchymal Stromal Cell Secretome.International journal of molecular sciences · 2020Article
- Improving the immunosuppressive potential of articular chondroprogenitors in a three-dimensional culture setting.Scientific reports · 2020Article
- Blockade of CD73 delays glioblastoma growth by modulating the immune environment.Cancer immunology, immunotherapy : CII · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma multiform is the most common and aggressive type of brain tumor. The overexpression of ecto-5'-nucleotidase/CD73 (ecto-5'-NT/CD73), an adhesion molecule and the main enzymatic source of extracellular adenosine, has been reported in tumor cells, and it is emerging as a component of glioma progression. Here, we evaluated the involvement of ecto-5'-NT/CD73 in cell adhesion through its interaction with different components of the extracellular matrix in the human U138MG glioma cell line. The results indicated that adenosine induced an increase in glioma cell adhesion. The treatment of glioma cells with adenosine receptor antagonists, APCP (α,β-methylene ADP) and dipyridamole prevented the adenosine effect, indicating the participation of extracellular and intracellular signaling pathways in cell adhesion mediated by adenosine. The ECM protein laminin (lam) and chondroitin sulfate (ChS) modulated the ecto-5'-NT/CD73 activity and glioma adhesion in a parallel manner, suggesting the involvement of purinergic signaling in the effects mediated by the extracellular matrix. Taken together, these results suggest that ecto-5'-NT/CD73, an important producer of extracellular adenosine, may modulate glioma cell adhesion and tumor cell-extracellular matrix interactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.